



13<sup>th</sup> November 2009

Companies Announcement Office  
ASX Limited  
Exchange Centre  
20 Bridge Street  
Sydney NSW 2000

**ASX ANNOUNCEMENT / MEDIA RELEASE**  
**Notice under s708A(5)(e) of the Corporations Act 2001**

This notice is given by Anteo Diagnostics Limited (**ADO**) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the **Act**).

ADO advises that:

- (a) ADO has today issued 39,500,000 ordinary shares at a price of A\$0.006 per share under a placement to sophisticated investors as announced to the market on 10<sup>th</sup> November 2009 (the **Placement Shares**);
- (b) the Placement Shares were issued without disclosure under Part 6D.2 of the Act;
- (c) this notice is being given under section 708A(5)(e) of the Act;
- (d) as at the date of this notice, ADO has complied with:
  - (i) the provisions of Chapter 2M of the Act as they apply to ADO; and
  - (ii) section 674 of the Act; and
- (e) as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Act.

**For further information please contact:**

**Dr Geoff Cumming, CEO, Anteo Diagnostics Limited**  
Tel: +612 8823 3110

**Mr James Henderson, Non Executive Chairman, Anteo Diagnostics Limited**  
Tel: +612 8823 3100

***Anteo Diagnostics Limited*** ABN 78 090 487 273  
Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

**Phone** 07 3219 0085 **Fax** 07 3219 0553 **Email** [contact@anteodx.com](mailto:contact@anteodx.com) **Web** [www.anteodx.com](http://www.anteodx.com)

For personal use only



**anteo diagnostics**  
l i m i t e d

#### About Anteo

**Anteo Diagnostics** is an Australian company specializing in the design and assembly of multi-component coatings for the solid phase of immunoassay and the use of those coatings in biomarker development. Anteo's proprietary coatings bind, orient and protect proteins such as antibodies in specific ways that enhance functionality. This results in dramatically improved immunoassay performance such as better sensitivity, and cost savings such as batch-to-batch reproducibility. Anteo applies its coatings to develop novel biomarkers for a range of diseases. Anteo works with many types of solid phase materials and formats, like beads of different kinds, membranes and plates. For more information, visit [www.anteodx.com](http://www.anteodx.com).

For personal use only

***Anteo Diagnostics Limited*** ABN 78 090 487 273

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

**Phone** 07 3219 0085 **Fax** 07 3219 0553 **Email** [contact@anteodx.com](mailto:contact@anteodx.com) **Web** [www.anteodx.com](http://www.anteodx.com)